Clinical Trials Directory

Trials / Completed

CompletedNCT04263844

Intranasal Dexmedetomidine Versus Intranasal Midazolam for Emergence Delirium Prevention

Comparison of Efficacy of Premedication Between Dexmedetomidine and Midazolam Intranasal for the Prevention of Emergence Delirium in Children Undergoing Ophthalmic Surgery

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Indonesia University · Academic / Other
Sex
All
Age
1 Year – 12 Years
Healthy volunteers
Not accepted

Summary

This study is a double-blind clinical trial, in pediatric patients aged 1-12 years with physical status ASA (American Society of Anesthesiology) 1 and 2 who underwent eye surgery under general anesthesia using Sevoflurane inhalation agents, in investigator institution during February-May 2019.. There were 64 children obtained by consecutive sampling, who underwent eye surgery in investigator institution during February-May 2019. The subjects then grouped into dexmedetomidine group and midazolam group. Effectiveness was assessed from Emergence Delirium (ED) events, recovery time, and post-premedication desaturation events. Data analysis using Chi Square test and Mann-Whitney test.

Detailed description

There were 64 children obtained by consecutive sampling, The subjects then grouped into dexmedetomidine group and midazolam group. Effectiveness was assessed from ED events, recovery time, and post-premedication desaturation events.

Conditions

Interventions

TypeNameDescription
DRUGIntranasal dexmedetomidinesubject will receive premedication with intranasal dexmedetomidine thirty minutes before induction
DRUGIntranasal Midazolamsubject will receive premedication with intranasal midazolam thirty minutes before induction

Timeline

Start date
2019-01-10
Primary completion
2019-10-10
Completion
2019-10-10
First posted
2020-02-11
Last updated
2020-02-12

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT04263844. Inclusion in this directory is not an endorsement.